<DOC>
	<DOCNO>NCT01223027</DOCNO>
	<brief_summary>This study evaluate safety efficacy Dovitinib versus sorafenib patient metastatic renal cell cancer .</brief_summary>
	<brief_title>Study Dovitinib Versus Sorafenib Patients With Metastatic Renal Cell Carcinoma</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<criteria>Patients metastatic renal cell carcinoma ( mRCC ) histological cytological confirmation clear cell carcinoma component clear cell Patients must receive one one prior VEGFtargeted therapy one one prior mTOR inhibitor therapy metastatic setting . One VEGF target therapy ( e.g . sunitinib , pazopanib , axitinib , tivozanib bevacizumab ) one prior mTOR inhibitor therapy ( everolimus , temsirolimus ridaforolimus ) Prior cytokine therapy prior vaccine adjuvant set permit . Patients must disease progression within 6 month stop last therapy . Patients must least one measurable lesion baseline ( RECIST Criteria Guidelines v1.1 ) assess Computer Tomography ( CT ) Scan Magnetic Resonance Imaging ( MRI ) . Karnofsky performance status ≥ 70 % Patients must follow laboratory value : Absolute Neutrophil Count ( ANC ) ≥ 1.5 x 109/L Platelets ≥ 100 x 109/L Hemoglobin ( Hgb ) &gt; 9 g/dL Serum total bilirubin : ≤ 1.5 x ULN ALT AST ≤ 3.0 x ULN ( Patients know liver metastasis : AST ALT ≤ 5.0 x ULN ) Serum creatinine ≤ 1.5 x ULN Patients previously receive sorafenib therapy neoadjuvant , adjuvant metastatic setting . Patients previously receive Dovitinib brivanib neoadjuvant , adjuvant metastatic setting . Patients brain metastasis . Radiological imaging ( e.g . CT MRI scan ) brain required screening/baseline Patients another primary malignancy within 3 year prior start study treatment , exception adequately treat basal cell carcinoma , squamous cell carcinoma nonmelanomatous skin cancer , insitu carcinoma uterine cervix Patients receive last administration anticancer target small molecule therapy ≤ 2 week prior start study treatment ( e.g . sunitinib , pazopanib , axitinib , everolimus , temsirolimus ) , recover side effect therapy Patients receive last administration nitrosurea mitomycinC ≤ 6 week prior start study treatment , recover side effect therapy Patients undergone major surgery ( e.g. , intrathoracic , intraabdominal intrapelvic ) ≤ 4 week prior start study treatment recover side effect therapy Patients history pulmonary embolism ( PE ) , untreated deep venous thrombosis ( DVT ) within past 6 month Patients concurrent severe and/or uncontrolled medical condition could compromise participation study Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>Dovitinib</keyword>
	<keyword>TKI</keyword>
	<keyword>Renal cell cancer</keyword>
	<keyword>RCC</keyword>
	<keyword>mRCC</keyword>
</DOC>